Mobile apps improve control for those with type 2 diabetes

Tracking your steps isn’t the only thing mobile applications are able to monitor. Researchers in the U.K. studied the effects of mobile apps in helping people with diabetes. Turns out, the technology may be a valuable option in helping track glucose levels.

Researchers, led by Ben Carter from Cardiff University's School of Medicine, set out to discover the impact the apps have on patients' self-management of diabetes.

"With the number of patients globally with diabetes expected to rise to over 500m by 2030, there is an urgent need for better self-management tools,” said Carter. "As we enter an era where portable technology is increasingly used to improve our lifestyles, as can already be seen with physical activity technology, apps can offer a large percentage of the world's population a low cost and dynamic solution to type 2 diabetes management."

Researchers analyzed data from 14 studies that included 1,360 participants on the effects the mobile apps had on the control of blood sugar levels. The use of mobile applications showed an average reduction in blood sugar levels by 0.49 percent. The studies also found participants of a younger age were more likely to use mobile apps. The positive effects also increased when paired with physician feedback.

The team agreed that the technology needs to be standardized, while policies for improving self-management care are developed. But the potential to improve care is evident.

"By the end of the decade it is predicted that global usage of mobile phones will exceed five billion, so apps, used in combination with other self-management strategies, could form the basis of diabetes education and self-management,” Carter said.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.